Deveney C W, Stein S, Way L W
Am J Surg. 1983 Jul;146(1):116-23. doi: 10.1016/0002-9610(83)90271-4.
From 1977 to 1983 we used cimetidine as primary therapy for 17 patients with the Zollinger-Ellison syndrome. All patients were treated with oral doses of cimetidine, 300 to 600 mg, four times a day, unless symptoms of hyperacidity developed or until evidence of a potentially resectable tumor became available, at which time they underwent definitive therapy. Eleven (65 percent) had no response to cimetidine therapy, 7 of whom had symptomatic recurrent ulcers, 3 of whom had esophagitis, and 2 of whom had severe diarrhea. Eight of these patients were treated with total gastrectomy, two with successful tumor resection, and one with parietal cell vagotomy (which facilitated the control of hyperacidity with cimetidine). All operations except one were performed electively and there was no operative mortality.
1977年至1983年期间,我们使用西咪替丁对17例卓-艾综合征患者进行了初始治疗。所有患者均接受口服西咪替丁治疗,剂量为300至600毫克,每日4次,除非出现胃酸过多症状或直到有证据表明存在可能可切除的肿瘤,此时他们接受确定性治疗。11例(65%)对西咪替丁治疗无反应,其中7例有症状性复发性溃疡,3例有食管炎,2例有严重腹泻。这些患者中有8例行全胃切除术,2例成功切除肿瘤,1例行壁细胞迷走神经切断术(这有助于用西咪替丁控制胃酸过多)。除1例手术外,所有手术均为择期进行,且无手术死亡病例。